^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Maturation inhibitor

    Related drugs:
    8ms
    A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1 (clinicaltrials.gov)
    P2, N=21, Terminated, ViiV Healthcare | Suspended --> Terminated; Sponsor decision
    Trial termination
    8ms
    VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI) (clinicaltrials.gov)
    P1, N=0, Withdrawn, ViiV Healthcare | N=67 --> 0 | Trial completion date: Jan 2026 --> Aug 2024 | Suspended --> Withdrawn | Trial primary completion date: Jan 2026 --> Aug 2024
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    midazolam hydrochloride
    1year
    Long intergenic noncoding RNA for IGF2BP2 stability suppresses gastric cancer cell apoptosis by inhibiting the maturation of microRNA-34a. (PubMed, Open Med (Wars))
    In addition, the effect of LINRIS overexpression was reversed by miR-34a overexpression. Therefore, LINRIS siRNA silencing in GC may promote cell apoptosis by promoting miR-34a maturation.
    Journal
    |
    MIR34A (MicroRNA 34a-5p) • IGF2BP2 (Insulin Like Growth Factor 2 MRNA Binding Protein 2)
    |
    miR-34a overexpression • miR-34a underexpression
    1year
    A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1 (clinicaltrials.gov)
    P2, N=26, Suspended, ViiV Healthcare | Trial completion date: Jun 2024 --> Nov 2024 | Not yet recruiting --> Suspended | Trial primary completion date: Jun 2024 --> Nov 2024
    Trial completion date • Trial suspension • Trial primary completion date
    1year
    VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI) (clinicaltrials.gov)
    P1, N=67, Suspended, ViiV Healthcare | Trial completion date: Mar 2025 --> Jan 2026 | Not yet recruiting --> Suspended | Trial primary completion date: Mar 2025 --> Jan 2026
    Trial completion date • Trial suspension • Trial primary completion date
    |
    midazolam hydrochloride
    1year
    Tumor-derived DEFB1 induces immune tolerance by inhibiting maturation of dendritic cell and impairing CD8+ T cell function in esophageal squamous cell carcinoma. (PubMed, Chin J Cancer Res)
    Tumor-derived DEFB1 can inhibit the maturation of DC and weaken the function of CD8+ T cells, accounting for the immune tolerance in ESCC. The role of DEFB1 in ESCC deserves further exploration.
    Journal
    |
    CD8 (cluster of differentiation 8)
    over1year
    VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI) (clinicaltrials.gov)
    P1, N=91, Not yet recruiting, ViiV Healthcare
    New P1 trial
    |
    midazolam hydrochloride
    over1year
    Activation of hepatic adenosine A1 receptor ameliorates MASH via inhibiting SREBPs maturation. (PubMed, Cell Rep Med)
    Higher hepatic A1R expression is observed in patients with MAFL/MASH and high-fat diet (HFD)-fed mice, which is supposed to be a physiologically adaptive response because A1R agonists attenuate MAFL/MASH in an A1R-dependent manner. These results highlight that hepatic A1R is a potential target for MAFL/MASH therapy.
    Journal
    |
    SQSTM1 (Sequestosome 1) • SREBF1 (Sterol Regulatory Element Binding Transcription Factor 1)
    almost2years
    TNFα: TNFR1 signaling inhibits maturation and maintains the pro-inflammatory programming of monocyte-derived macrophages in murine chronic granulomatous disease. (PubMed, Front Immunol)
    MoMacs lacking TNFR1 matured more normally in the CGD milieu both ex vivo and following adoptive transfer in vivo. These data lend mechanistic insights into the utility of TNFα blockade in CGD and to other diseases where such therapy has been shown to be beneficial.
    Preclinical • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • TNFRSF1A (TNF Receptor Superfamily Member 1A) • IL1B (Interleukin 1, beta) • CXCL1 (Chemokine (C-X-C motif) ligand 1)
    almost2years
    DYNAMIC: A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults (clinicaltrials.gov)
    P2, N=85, Terminated, ViiV Healthcare | Phase classification: P2b --> P2
    Phase classification
    |
    CD4 (CD4 Molecule)
    2years
    Bone metastatic mammary tumor cell-derived extracellular vesicles inhibit osteoblast maturation via JNK signaling. (PubMed, Arch Biochem Biophys)
    In contrast, the nullification of reduced JNK phosphorylation by anisomycin, a potent JNK activator, increased the expression levels of osteoblast differentiation markers. Overall, our data indicated that 4T1-EVs affect osteoblast maturation, at least partially, through the regulation of JNK activity, which provides novel insights into the pathological impact of osteolytic bone metastasis and the role of EVs in osteoblast differentiation.
    Journal • Tumor cell • Metastases
    |
    COL1A1 (Collagen Type I Alpha 1 Chain) • MAPK8 (Mitogen-activated protein kinase 8) • RUNX2 (RUNX Family Transcription Factor 2) • BGLAP (Bone Gamma-Carboxyglutamate Protein)
    2years
    DOMINO: A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults (clinicaltrials.gov)
    P2, N=169, Terminated, ViiV Healthcare | The decision is not based on any safety or efficacy concerns. It reflects the company strategy for portfolio progression.
    Phase classification • Trial completion date • Trial termination • Combination therapy
    |
    CD4 (CD4 Molecule)